Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,500 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 August 2020) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 207 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 72 results:
Author Title Type [ Year(Asc)]
Filters: Author is Azoulay, L.  [Clear All Filters]
2020
G. Simoneau, Moodie, E. E. M., Azoulay, L., and Platt, R. W., “Adaptive Treatment Strategies with Survival Outcomes: An Application to the Treatment of Type 2 Diabetes using a Large Observational Database”, Am J Epidemiol, 2020.
F. Khosrow-Khavar, Filion, K. B., Bouganim, N., Suissa, S., and Azoulay, L., “Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study”, Circulation, vol. 141, pp. 549-559, 2020.
D. Abrahami, Renoux, C., Yin, H., Fournier, J. P., and Azoulay, L., “The Association between Oral Anticoagulants and Cancer Incidence among Individuals with Nonvalvular Atrial Fibrillation”, Thromb Haemost, 2020.
F. Khosrow-Khavar, Bouganim, N., Filion, K. B., Suissa, S., and Azoulay, L., “Cardiotoxicity of Sequential Aromatase Inhibitors Use in Women with Breast Cancer”, Am J Epidemiol, 2020.
J. Rouette, Yin, H., Yu, O. H. Y., Bouganim, N., Platt, R. W., and Azoulay, L., “Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes”, Diabet Med, 2020.
C. Santella, Yin, H., Hicks, B. M., Yu, O. H. Y., Bouganim, N., and Azoulay, L., “Weight-lowering effects of glucagon-like peptide-1 receptor agonists and detection of breast cancer among obese women with diabetes”, Epidemiology, 2020.
2019
A. J. Klil-Drori, Santella, C., Tascilar, K., Yin, H., Aprikian, A., and Azoulay, L., “Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study”, Drug Saf, 2019.
S. Y. Loo, Azoulay, L., Nie, R., Dell'Aniello, S., Yu, O. H. Y., and Renoux, C., “Cardiovascular and cerebrovascular safety of testosterone replacement therapy among aging men with low testosterone levels: a cohort study.”, Am J Med, 2019.
A. Douros, Rouette, J., Yin, H., Yu, O. H. Y., Filion, K. B., and Azoulay, L., “Dipeptidyl Peptidase-4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes”, Diabetes Care, 2019.
K. B. Filion, Douros, A., Azoulay, L., Yin, H., Yu, O. H., and Suissa, S., “Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study”, Br J Clin Pharmacol, 2019.
C. Santella, Renoux, C., Yin, H., Yu, O. H. Y., and Azoulay, L., “Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men with Late-Onset Hypogonadism”, Am J Epidemiol, 2019.
R. Pradhan, Yin, H., Yu, O. H. Y., and Azoulay, L., “The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study”, Drug Saf, 2019.
2018
B. M. Hicks, Filion, K. B., Yin, H., Sakr, L., Udell, J. A., and Azoulay, L., “Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study”, Bmj, vol. 363, p. k4209, 2018.
F. Khosrow-Khavar, Yin, H., Barkun, A., Bouganim, N., and Azoulay, L., “Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer”, Ann Oncol, vol. 29, pp. 744-748, 2018.
D. Abrahami, Douros, A., Yin, H., Yu, O. H. Y., Renoux, C., Bitton, A., and Azoulay, L., “Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study”, Bmj, vol. 360, p. k872, 2018.
A. Douros, Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., and Azoulay, L., “Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy”, Diabetes Care, vol. 41, pp. 2330-2338, 2018.
D. Abrahami, Douros, A., Yin, H., Yu, O. H., Faillie, J. L., Montastruc, F., Platt, R. W., Bouganim, N., and Azoulay, L., “Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study”, Bmj, vol. 363, p. k4880, 2018.
D. Abrahami, Yin, H., Yu, O. H. Y., Pollak, M. N., and Azoulay, L., “Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes”, Epidemiology, vol. 29, pp. 246-253, 2018.
O. Yu, Azoulay, L., Yin, H., Filion, K. B., and Suissa, S., “Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia”, Am J Med, vol. 131, pp. 317.e11-317.e22, 2018.
A. Douros, Dell'Aniello, S., Yu, O. H. Y., Filion, K. B., Azoulay, L., and Suissa, S., “Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study”, Bmj, vol. 362, p. k2693, 2018.
A. Douros, Abrahami, D., Yin, H., Yu, O. H. Y., Renoux, C., Hudson, M., and Azoulay, L., “Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes”, Epidemiology, vol. 29, pp. 904-912, 2018.
2017
B. M. Hicks, Klil-Drori, A. J., Yin, H., Campeau, L., and Azoulay, L., “Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer”, Epidemiology, vol. 28, pp. 712-718, 2017.
F. Khosrow-Khavar, Rej, S., Yin, H., Aprikian, A., and Azoulay, L., “Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer”, J Clin Oncol, vol. 35, pp. 201-207, 2017.
B. M. Hicks, Yin, H., Bladou, F., Ernst, P., and Azoulay, L., “Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia”, Thorax, vol. 72, pp. 596-597, 2017.
J. W. Wu, Azoulay, L., Majdan, A., Boivin, J. F., Pollak, M., and Suissa, S., “Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes”, J Clin Oncol, vol. 35, pp. 3647-3653, 2017.
B. M. Hicks, Yin, H., Sinyavskaya, L., Suissa, S., Azoulay, L., and Brassard, P., “Metformin and the incidence of viral associated cancers in patients with type 2 diabetes”, Int J Cancer, vol. 141, pp. 121-128, 2017.
A. Douros, Yin, H., Yu, O. H. Y., Filion, K. B., Azoulay, L., and Suissa, S., “Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events”, Diabetes Care, vol. 40, pp. 1506-1513, 2017.
A. J. Klil-Drori, Yin, H., Abenhaim, H. A., Fort, G. G. du, and Azoulay, L., “Prolactin-Elevating Antipsychotics and the Risk of Endometrial Cancer”, J Clin Psychiatry, vol. 78, pp. 714-719, 2017.
V. Mandilaras, Bouganim, N., Yin, H., Asselah, J., and Azoulay, L., “The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer”, Br J Cancer, vol. 116, pp. 103-108, 2017.
2016
A. J. Klil-Drori, Tascilar, K., Yin, H., Aprikian, A., Bitton, A., and Azoulay, L., “Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer”, Am J Epidemiol, vol. 184, pp. 15-22, 2016.
A. J. Klil-Drori, Yin, H., Tagalakis, V., Aprikian, A., and Azoulay, L., “Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism”, Eur Urol, vol. 70, pp. 56-61, 2016.
J. L. Faillie, Yu, O. H., Yin, H., Hillaire-Buys, D., Barkun, A., and Azoulay, L., “Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus”, JAMA Intern Med, vol. 176, pp. 1474-1481, 2016.
B. M. Hicks, Yin, H., Yu, O. H., Pollak, M. N., Platt, R. W., and Azoulay, L., “Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink”, Bmj, vol. 355, p. i5340, 2016.
K. B. Filion, Azoulay, L., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Hu, N., Paterson, J. M., Targownik, L., Turin, T. C., Udell, J. A., and Ernst, P., “A Multicenter Observational Study of Incretin-based Drugs and Heart Failure”, N Engl J Med, vol. 374, pp. 1145-54, 2016.
Y. Lian, Yin, H., Pollak, M. N., Carrier, S., Platt, R. W., Suissa, S., and Azoulay, L., “Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer”, Eur Urol, vol. 70, pp. 808-815, 2016.
M. Tuccori, Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., and Azoulay, L., “Pioglitazone use and risk of bladder cancer: population based cohort study”, Bmj, vol. 352, p. i1541, 2016.
L. Azoulay, Soldera, S., Yin, H., and Bouganim, N., “Use of Calcium Channel Blockers and Risk of Breast Cancer: A Population-based Cohort Study”, Epidemiology, vol. 27, pp. 594-601, 2016.
K. Tascilar, Azoulay, L., Dell'Aniello, S., Bartels, D. B., and Suissa, S., “The Use of Telmisartan and the Incidence of Cancer”, Am J Hypertens, vol. 29, pp. 1358-1365, 2016.
2015
L. Azoulay, Eberg, M., Benayoun, S., and Pollak, M., “5alpha-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer”, JAMA Oncol, vol. 1, pp. 314-20, 2015.
O. H. Yu, Yin, H., and Azoulay, L., “The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death”, Can J Diabetes, vol. 39, pp. 383-9, 2015.
J. L. Faillie, Filion, K. B., Patenaude, V., Ernst, P., and Azoulay, L., “Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes”, Diabetes Obes Metab, vol. 17, pp. 379-85, 2015.
O. H. Yu, Filion, K. B., Azoulay, L., Patenaude, V., Majdan, A., and Suissa, S., “Incretin-based drugs and the risk of congestive heart failure”, Diabetes Care, vol. 38, pp. 277-84, 2015.
J. P. Fournier, Yin, H., Nessim, S. J., Montastruc, J. L., and Azoulay, L., “Tramadol for noncancer pain and the risk of hyponatremia”, Am J Med, vol. 128, pp. 418-25.e5, 2015.
J. P. Fournier, Azoulay, L., Yin, H., Montastruc, J. L., and Suissa, S., “Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain”, JAMA Intern Med, vol. 175, pp. 186-93, 2015.
F. Lapi, Azoulay, L., Kezouh, A., Benisty, J., Matok, I., Mugelli, A., and Suissa, S., “The use of antidepressants and the risk of chronic atrial fibrillation”, J Clin Pharmacol, vol. 55, pp. 423-30, 2015.
J. Assayag, Pollak, M. N., and Azoulay, L., “The use of aspirin and the risk of mortality in patients with prostate cancer”, J Urol, vol. 193, pp. 1220-5, 2015.
M. Tuccori, Wu, J. W., Yin, H., Majdan, A., and Azoulay, L., “The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes”, Diabetes Care, vol. 38, pp. 2083-9, 2015.
2014
S. Couraud, Dell'Aniello, S., Bouganim, N., and Azoulay, L., “Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia”, Breast Cancer Res Treat, vol. 146, pp. 619-26, 2014.
S. Couraud, Azoulay, L., Dell'Aniello, S., and Suissa, S., “Cardiac glycosides use and the risk of lung cancer: a nested case-control study”, BMC Cancer, vol. 14, p. 573, 2014.
I. Matok, Azoulay, L., Yin, H., and Suissa, S., “Immortal time bias in observational studies of drug effects in pregnancy”, Birth Defects Res A Clin Mol Teratol, vol. 100, pp. 658-62, 2014.
[Page last reviewed 5 August 2020]